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A B S T R A C T
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only available pharmaco-
logical therapy to improve the outcome of acute ischemic stroke. We compared 71 patients presenting with ischaemic
stroke and given intravenous rt-PA (0·9 mg/kg total dose) within 3 h with 71 patients who present to the hospital more
than 3 hours after stroke symptom onset. The primary endpoint was the modified Rankin scale (mRS) at 90 days, dicho-
tomised for favourable and unfavourable (score 2–6). Outcome measures were symptomatic intracerebral haemorrhage
within 36 h (haemorrhage associated with National Institutes of Health Stroke Scale [NIHSS] 4 points deterioration),
and mortality at 3 months. More patients had favourable outcome with the rt-PA-treated group than with the control
group (64.79% vs. 22.54%; p= 0.0001). The greater proportion of patients left with minimal or no deficit 90 days after
rt-PA treatment, as compared with the control group. In the treated group symptomatic intracranial hemorrhage oc-
curred in 1 patient who recovered to a level of functional independence, and asymptomatic intracranial hemorrhage was
observed in 2 patients. Our experience of an acute stroke thrombolysis service shows that we are able to provide this treat-
ment safely and in accordance with established treatment guidelines. We recommend thrombolytic treatment in acute
ischemic stroke for selected population.
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Introduction
Thrombolysis with intravenous (IV) recombinant tis-
sue plasminogen activator (rt-PA) is the only available
pharmacological therapy to improve the outcome of acu-
te ischemic stroke. The aims of thrombolytic therapy are
arterial recanalisation and salvage of the ischaemic pen-
umbra, a region of critically hypoperfused but viable
brain tissue around the irreversibly damaged infarct
core1. Number of randomized, placebo controlled, clinical
trials studying intravenous rt-PA in acute stroke have
been conducted2–5 and the US Food and Drug Adminis-
tration (FDA) approved the use of IV rt-PA in 1996, on
the basis of the results of the National Institute of Neu-
rological Disorders and Stroke (NINDS) rt-PA Stroke
Study2. Stroke specialists in many countries, including
Croatia, adopted guidelines launched by the American
Heart Association (AHA) in the management of acute
ischemic stroke6. We describe the results of our con-
trolled, parallel-group prospective study to investigate
the clinical effectiveness of rt-PA administered in pa-
tients with acute ischemic stroke.
Patients and Methods
Protocol for rt-PA treatment
All acute ischemic strokes that presented at Univer-
sity Hospital Rijeka during 2000–2009 were screened for
the eligibility for IV thrombolytic treatment. Inclusion
criteria were hemispheric ischemic stroke and criteria
that were published in the NINDS and ECAS II trial2,3.
Control group represent the patients who present to the
hospital more than 3 hours after stroke symptomonset.
Ethics committee approved the study protocol and the
patient, next of kin, or legal representative, according to
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individual institutional protocols, provided written
consent.
Initial assessments included a physical examination,
brain CT and quantification of any neurological deficit
with the use of the National Institute of Health stroke
scale (NIHSS), a 15 item scale that measures the level of
neurologic impairment: total scores range from 0 to 42,
with higher values reflecting more severe stroke7.
Patients allocated to the treatment had to receive
rt-PA (Actilyse, Boehringer Ingelheim, Germany) in a
dose of 0.9 mg/kg body weight (maximum 90 mg), started
within 3 h of ischemic stroke onset. Of the total dose,
10% was administered as a bolus and the remainder was
given by continuous intravenous infusion over a period
of 60 min. Both groups were treated in the same way in
all other respects.
After thrombolysis, treatment included preventive ther-
apy of ordinary poststroke complications, initiation of
secondary prevention, and early rehabilitation.
Repeat CT scan of the brain was scheduled at 24h af-
ter the thrombolytic therapy. In case of neurological
worsening, CT scan would be performed soon after the
detection of deterioration. Intracerebral hemorrhage was
diagnosed by CT scan. Symptomatic hemorrhage was de-
fined as hemorrhagic lesion on CT scan with clinical
worsening of NIHSS  4 points.
Outcome measures
The primary outcome measure was the score on the
modified Rankin scale (mRS) at day 90. The mRS evalu-
ates global disability and handicap; scores range from 0
(no symptoms or disability) to 6 (death)7. The primary
outcome was excellent functional outcome (mRS score
0–1) compared with disability or death (mRS score 2–6).
Secondary end points at day 90 included the Barthel
index (BI) (ranging from 100 [independent in all activi-
ties of daily living] to 0 [completely dependent])7, the
NIHSS and the Glasgow Outcome Scale (GOS)7. Death
within 3 months was also recorded.
Statistical analysis
All tests of significance were 2-sided and conducted at
the p=0.05 level of significance. Differences in baseline
characteristics were determined using t-test for continu-
ous variables and c2-tests for categorical variables. Effi-




Between August, 2000 and August, 2009, there were
71 consecutive patients who fulfilled the thrombolysis
criteria along with 71 patients from the control group.
The mean age of the treated group was 60±36 years, with
58% males. The median initial NIHSS score was 14.41
(range, 7–29). Other baseline characteristics, including
demographic data and risk factors, are given in Table 1.
There was no significant difference between the group
receiving rt-PA and the control group in regard to age,
risk factors and NIHSS score prior to the treatment
(p>0.05).
The median door-to-needle time (time interval from
admission to our emergency room till administration of
rt-PA) was 35 minutes.
Functional outcomes
Clinical outcomes are shown in Figure 1.
The number of patients with favorable outcomes for
each of the four outcome measures three months after
stroke was higher in the rt-PA group than in the control
group.
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TABLE 1





Age (yr) 60.3±23.3 60±36
Gender (% of males) 58 58
Hypertension (%) 97 97
Diabetes (%) 38 35
Hyperlipidemia (%) 46 45
Atrial flutter or fibrillation (%) 24 25
Smoking status (%) 32 30
Alcohol abuse (%) 18 17
Fig. 1. The outcome at 90 days after the treatment. Scores of 0–1
on the mRS, 95–100 on the BI, 1 on the NIHSS, and 0–1 on the
GOS were considered to indicate a favorable outcome. Values do
not total 100 percent because of rounding. The results of all four
outcome measures, statistically significant favor the rt-PA group.
The greater proportion of patients left with minimal or no deficit
90 days after rt-PA treatment, as compared with the control
group.
The observed rate of an excellent outcome in the
treated group, the patients with no or minimal symp-
toms (mRS 0 to 1) was significantly higher in contrast to
the control group (64.79% vs. 22.54%; p=0.0001).
On BI, 63.39% of patients were independent (BI 95 to
100) in the treated group in comparison to 19.72% in the
control group (p<0.0001)
There was also an increase in the number of patients
with an NIHSS score of 0 or 1 in the treated group than
in the control group (21.13% vs. 1.41%; p=0.001).
A similar magnitude of effect was seen with respect to
the improvement in the rt-PA group with the use of the
Glasgow outcome scale (64.79% vs. 21.13%; p<0.0001).
By 90 days after the onset of stroke, 1 of the 71 rt-
-PA-treated patients had died (1.41%), as compared with
13 of the 71 control patients (18.31%) (p=0.002.).
In the treated group symptomatic intracranial hem-
orrhage occurred in 1 patient who recovered to a level of
functional independence, and asymptomatic intracranial
hemorrhage was observed in 2 patients.
Discussion
We report our experience on rt-PA treatment in acute
ischemic stroke. To our knowledge, this is the first report
of prospective control-parallel group case series in Croa-
tia. rt-PA is licensed treatment for acute stroke in the
USA, Canada, Australia and the European Union, and
cost-effectiveness analysis suggests that rt-PA for stroke
is cost-saving due to reduction in nursing home and re-
habilitation costs3,5.
Researchers assessed the effectiveness of rt-PA as a
routine treatment for acute stroke at many centres1–4,
and from year 2000 till 2004 in Croatia it was offered as a
standard treatment only in our stroke unit.
A European community stroke study recorded that
25% of patients admitted to hospital with stroke had pre-
sented within 3 hours8, and an American community
stroke study recorded 20–28% of patients presenting
within 2 hours of stroke onset9. In this study, we were
able to administer thrombolytic agent within 3 h in all
cases. Our mean door-to-needle time was comparable to
other studies performed. Our major obstacle for getting
more patients is the delayed in hospitalization. We be-
lieve that public health initiatives and education would
increase the number of patients eligible for treatment in
the future.
In our study, the rate of major improvement was
higher than those previously reported. The overall excel-
lent functional outcome (mRS score 0–1) rate was 64.79%.
It is statistically higher than reported from the NINDS
study (39%) and ECAS II study (40.3%). We believe that
it is mainly due to the reason that in patients’ selection,
treatment, and evaluation provided protocol was strictly
followed.
Our experience of an acute stroke thrombolysis ser-
vice shows that we are able to provide this treatment
safely and in accordance with established treatment gui-
delines. Direct comparison of our study with that of the
NINDS and ECASS II studies is not possible. The base-
line characteristics appear similar, but in our cohort we
had less patients and all of them were from a single cen-
tre. In addition, the rate of symptomatic and asymptom-
atic intracerebral hemorrhages was much lower than in
other studies. Death rate recorded was: 1.41% vs. 17% in
NINDS rt-PA group and 10.6% in ECASS II rt-PA group.
Intracerebral bleeding occurred in three of our pa-
tients: it was clinically insignificant in one of the pa-
tients, while the other two patients appeared to have a
net benefit from treatment with rt-PA, despite the bleed.
Meta-analysis of community studies confirms that com-
parable outcomes to those of randomized trials can bea-
chieved, especially when established treatment guide-
lines are followed10–13.
Conclusion
In conclusion, thrombolytic treatment is recommen-
ded in acute ischemic stroke for selected population. De-
tailed published guidelines for use of thrombolytic ther-
apy and management of patients post-thrombolysis are
available and should be followed in order to reduce com-
plications and to obtain the most effective treatment. It
must be kept on mind that thrombolysis is specific ther-
apy. Because of that arterial recanalisation and good out-
come cannot be expected if arterial occlusion is not
caused by thrombus.
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INTRAVENOZNA TROMBOLIZA U LIJE^ENJU AKUTNOG MO@DANOG UDARA: NA[A ISKUSTVA
S A @ E T A K
Intravenozna tromboliza (IV) s rekombinantnim tkivnim aktivatorom plazminogena (rt-PA) je jedina dostupna far-
makolo{ka terapija za pobolj{anje ishoda lije~enja akutnog mo`danog udara. Usporedili smo 71 pacijenta s ishemijskim
mo`danim udarom koji su intravenozno primili rt-PA (0,9 mg/kg ukupna doza) unutar prva tri sata od nastupa mo`da-
nog udara sa 71 pacijentom koji su primljeni nakon 3 sata od nastupa mo`danog udara. Primarni cilj je modificirana
Rankin skala (mRS) nakon 90 dana, podjeljena na povoljan ishod (skor 0–1). Ishod je bio simptomatsko intracerebralno
krvarenje u prva 24 sata (krvarenje povezano s pogor{anjem NIHSS za  4 boda) i moratlitet u 3 mjeseca. Vi{e pacije-
nata lije~enih s rt-PA u odnosu na placebo je imalo povoljan ishod (64,79% vs. 22,54%; p=0,0001). Ve}i postotak pacije-
nata lije~enih rt-PA je napustio bolnicu s minimalnim ili nikakvim deficitom nakon 90 dana u usporedbi s kontrolnom
grupom. U grupi lije~enih imali smo jednog pacijenta s simptomatskim intracerebralnim krvarenjem koji se oporavio do
nivoa funkcionalne neovisnosti, te dva bolesnika s asimptomatskim intracerebralnim krvarenjem. Na{e iskustvo u lije-
~enju bolesnika s akutnim ishemijskim mo`danim udarom intravenoznom trombolizom pokazuje da smo sposobni pru-
`iti sigurno lije~enje prema va`e}im smjernicama. Preporu~ujemo tromboliti~ku terapiju kod ishemijskog mo`danog
udara kod selekcioniranih bolesnika.
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